Huber Capital Management LLC Has $4.42 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Huber Capital Management LLC increased its stake in Kenvue Inc. by 8.9%, owning 184,300 shares valued at $4.42 million as of the end of the first quarter.
• Kenvue recently announced a quarterly dividend increase to $0.2075 per share, reflecting an annual yield of 4.0% and a dividend payout ratio of 112.16%.
• Analysts have mixed opinions on Kenvue's stock, with five recommending a Buy, seven suggesting Hold, and one advising Sell, alongside an average price target of $24.38.

Huber Capital Management LLC increased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 8.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 184,300 shares of the company's stock after purchasing an additional 15,000 shares during the period. Huber Capital Management LLC's holdings in Kenvue were worth $4,420,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. raised its stake in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after acquiring an additional 4,034 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock worth $369,000 after purchasing an additional 3,081 shares during the period. Starboard Value LP purchased a new position in shares of Kenvue during the 4th quarter worth $467,864,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Kenvue in the 1st quarter worth $413,000. Finally, Cooper Investors PTY Ltd. raised its position in shares of Kenvue by 39.7% in the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock worth $20,577,000 after buying an additional 244,043 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

NYSE:KVUE traded up $0.18 on Monday, reaching $20.72. The stock had a trading volume of 10,307,391 shares, compared to its average volume of 17,119,262. The company has a market capitalization of $39.76 billion, a P/E ratio of 27.99, a price-to-earnings-growth ratio of 2.97 and a beta of 0.83. Kenvue Inc. has a 1-year low of $19.75 and a 1-year high of $25.17. The stock has a fifty day moving average price of $21.46 and a 200-day moving average price of $22.45. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business's revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 4.0%. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. Zacks Research upgraded Kenvue to a "strong sell" rating in a report on Monday, August 11th. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Bank of America cut their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Citigroup lowered their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.